Numeral (JSE:XII) YoY EBITDA Growth: -10.35% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JSE:XII Numeral Ltd JSE:XII
32 GF Score
Price R0.30
! 5 Warning Signs
View Full Analysis

What is Numeral YoY EBITDA Growth?

Numeral JSE:XII 32 YoY EBITDA Growth is -10.35% as of May. 2026. GuruFocus rates JSE:XII with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Numeral's YoY EBITDA Growth for the quarter that ended in May. 2026 was -10.35%.

Numeral's EBITDA per Share for the six months ended in May. 2026 was R0.03.

Numeral YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Numeral's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Numeral YoY EBITDA Growth Chart

Numeral Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.17 -100.00 120.00 1,800.00 88.16

Numeral Semi-Annual Data
May21 Aug21 Nov21 Feb22 May22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.56 -45.46 270.83 -10.35
JSE:XII
32GF Score
Numeral Ltd JSE:XII
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Numeral YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Numeral's YoY EBITDA Growth for the fiscal year that ended in Feb. 2026 is calculated as:

YoY EBITDA Growth (A: Feb. 2026 )
=(EBITDA per Share (A: Feb. 2026 )-EBITDA per Share (A: Feb. 2025 ))/ | EBITDA per Share (A: Feb. 2025 ) |
=(0.143-0.076)/ | 0.076 |
=88.16 %

Numeral's YoY EBITDA Growth for the quarter that ended in May. 2026 is calculated as:

YoY EBITDA Growth (Q: May. 2026 )
=(EBITDA per Share (Q: May. 2026 )-EBITDA per Share (Q: Feb. 2026 )) / | EBITDA per Share (Q: Feb. 2026 ) |
=(0.026-0.089)/ | 0.089 |
=-70.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -10.35% mean?
Numeral (JSE:XII) has a YoY EBITDA Growth of -10.35% as of May. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Numeral and its competitors.
Is Numeral's YoY EBITDA Growth too high?
Numeral's current YoY EBITDA Growth is -10.35%. Overall, Numeral has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Numeral's YoY EBITDA Growth compare to ZTS and UTHR?
Numeral's YoY EBITDA Growth of -10.35% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Numeral and its competitors. Numeral's current YoY EBITDA Growth is -10.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numeral stock overvalued right now?
Numeral (JSE:XII) has a current YoY EBITDA Growth of -10.35%. The current YoY EBITDA Growth is -10.35%. Numeral's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Numeral (JSE:XII), the current YoY EBITDA Growth is -10.35% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Numeral Business Description

Other Exchanges NXII.N0000:Mauritius
Address Sayed Hossen Road, Unit 13 Socota Phoenicia, Phoenix, MUS
Numeral Ltd is a Mauritius-based investment holding company with operations spanning biotechnology and healthcare services, financial services and asset management, and corporate group services. Its biotechnology segment, which generates the largest share of revenue, provides stem-cell related services including the harvesting, processing and storage of stem cells, along with associated healthcare and biotechnology activities. The financial services segment covers investment activities and asset management, while the holdings segment provides corporate and group-level services. The company operates across Africa, Europe and Asia, serving healthcare clients, storage customers and investment clients. A significant portion of revenue is generated through trading income in addition to service fees from stem-cell storage and healthcare services. Numeral Ltd is listed on the Stock Exchange of Mauritius.
32GF Score

Get the complete analysis for JSE:XII

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R0.30
Price